Deletion of metabotropic glutamate receptors 2 and 3 (mGlu2 & mGlu3) in mice disrupts sleep and wheel-running activity, and increases the sensitivity of the circadian system to light

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Pritchett, David ^a   Jagannath, Aarti ^a,b   Brown, Laurence A ^a   Tam, Shu K E ^a   Hasan, Sibah ^a   Gatti, Silvia ^b   Harrison, Paul J ^c   Bannerman, David M ^c   Foster, Russell G ^a   Peirson, Stuart N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b F Hoffmann La Roche   (Switzerland)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; RO 4432717; UNCLASSIFIED DRUG; METABOTROPIC RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CIRCADIAN RHYTHM; CONTROLLED STUDY; GENE DELETION; IMMOBILITY; KNOCKOUT MOUSE; LIGHT DARK CYCLE; LOCOMOTION; MALE; MOUSE; NONHUMAN; SLEEP; SLEEP FRAGMENTATION; SLEEP TIME; TRANSGENIC MOUSE; WILD TYPE; ALLOSTERISM; ANIMAL; C57BL MOUSE; GENETICS; LIGHT; PHYSIOLOGY;

MUS;

ALLOSTERIC REGULATION; ANIMALS; CIRCADIAN RHYTHM; LIGHT; LOCOMOTION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHYSICAL CONDITIONING, ANIMAL; RECEPTORS, METABOTROPIC GLUTAMATE; SLEEP;

EID: 84929207618     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125523     Document Type: Article

References (97)

1. van Os J, Kapur S. Schizophrenia. The Lancet. 2009; 374(9690):635-45. doi: 10.1016/S0140-6736(09)60995-8 PMID: 19700006
2. Cohrs S. Sleep disturbances in patients with schizophrenia: impact and effect of antipsychotics. CNS drugs. 2008; 22(11):939-62. PMID: 18840034
3. Manoach DS, Stickgold R. Does abnormal sleep impair memory consolidation in schizophrenia? Frontiers in human neuroscience. 2009; 3:21. doi: 10.3389/neuro.09.021.2009 PMID: 19750201
4. Monti JM, BaHammam AS, Pandi-Perumal SR, Bromundt V, Spence DW, Cardinali DP, et al. Sleep and circadian rhythm dysregulation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 43:209-16. doi: 10.1016/j.pnpbp.2012.12.021 PMID: 23318689
5. Martin J, Jeste DV, Caliguiri MP, Patterson T, Heaton R, Ancoli-Israel S. Actigraphic estimates of circadian rhythms and sleep/wake in older schizophrenia patients. Schizophr Res. 2001; 47(1):77-86. PMID: 11163547
6. Martin JL, Jeste DV, Ancoli-Israel S. Older schizophrenia patients have more disrupted sleep and circadian rhythms than age-matched comparison subjects. J Psychiatr Res. 2005; 39(3):251-9. PMID: 15725423
7. Wulff K, Dijk DJ, Middleton B, Foster RG, Joyce EM. Sleep and circadian rhythm disruption in schizophrenia. Br J Psychiatry. 2012; 200(4):308-16. doi: 10.1192/bjp.bp.111.096321 PMID: 22194182
8. Wulff K, Joyce E, Middleton B, Dijk DJ, Foster RG. The suitability of actigraphy, diary data, and urinary melatonin profiles for quantitative assessment of sleep disturbances in schizophrenia: a case report. Chronobiology international. 2006; 23(1-2):485-95.
9. Wulff K, Porcheret K, Cussans E, Foster RG. Sleep and circadian rhythm disturbances: multiple genes and multiple phenotypes. Current opinion in genetics & development. 2009; 19(3):237-46.
10. Pritchett D, Wulff K, Oliver PL, Bannerman DM, Davies KE, Harrison PJ, et al. Evaluating the links between schizophrenia and sleep and circadian rhythm disruption. J Neural Transm. 2012; 119 (10):1061-75. PMID: 22569850
11. Wulff K, Gatti S, Wettstein JG, Foster RG. Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease. Nat Rev Neurosci. 2010; 11(8):589-99. doi: 10.1038/nrn2868 PMID: 20631712
12. Tamminga CA. Schizophrenia and glutamatergic transmission. Critical reviews in neurobiology. 1998; 12(1-2):21-36. PMID: 10348615
13. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annual review of pharmacology and toxicology. 2002; 42:165-79. PMID: 11807169
14. Ebling FJ. The role of glutamate in the photic regulation of the suprachiasmatic nucleus. Progress in neurobiology. 1996; 50(2-3):109-32. PMID: 9015827
15. Reppert SM, Weaver DR. Molecular analysis of mammalian circadian rhythms. Annual review of physiology. 2001; 63:647-76. PMID: 11181971
16. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature. 2002; 418(6901): 935-41. PMID: 12198538
17. Michel S, Marek R, Vanderleest HT, Vansteensel MJ, Schwartz WJ, Colwell CS, et al. Mechanism of bilateral communication in the suprachiasmatic nucleus. Eur J Neurosci. 2013; 37(6):964-71. doi: 10.1111/ejn.12109 PMID: 23311402
18. Cui LN, Coderre E, Renaud LP. Glutamate and GABA mediate suprachiasmatic nucleus inputs to spinal-projecting paraventricular neurons. American journal of physiology Regulatory, integrative and comparative physiology. 2001; 281(4):R1283-9. PMID: 11557637
19. Hermes ML, Coderre EM, Buijs RM, Renaud LP. GABA and glutamate mediate rapid neurotransmission from suprachiasmatic nucleus to hypothalamic paraventricular nucleus in rat. The Journal of physiology. 1996; 496(3):749-57. PMID: 8930841
20. Saint-Mleux B, Bayer L, Eggermann E, Jones BE, Muhlethaler M, Serafin M. Suprachiasmatic modulation of noradrenaline release in the ventrolateral preoptic nucleus. J Neurosci. 2007; 27(24):6412-6. PMID: 17567801
21. Sun X, Whitefield S, Rusak B, Semba K. Electrophysiological analysis of suprachiasmatic nucleus projections to the ventrolateral preoptic area in the rat. Eur J Neurosci. 2001; 14(8):1257-74. PMID: 11703455
22. Zhang L, Kolaj M, Renaud LP. Suprachiasmatic nucleus communicates with anterior thalamic paraventricular nucleus neurons via rapid glutamatergic and gabaergic neurotransmission: state-dependent response patterns observed in vitro. Neuroscience. 2006; 141(4):2059-66. PMID: 16797851
23. Kodama T, Lai YY, Siegel JM. Enhanced glutamate release during REM sleep in the rostromedial medulla as measured by in vivo microdialysis. Brain Res. 1998; 780(1):178-81. PMID: 9497097
24. Lopez-Rodriguez F, Medina-Ceja L, Wilson CL, Jhung D, Morales-Villagran A. Changes in extracellular glutamate levels in rat orbitofrontal cortex during sleep and wakefulness. Archives of medical research. 2007; 38(1):52-5. PMID: 17174723
25. Naylor E, Aillon DV, Gabbert S, Harmon H, Johnson DA, Wilson GS, et al. Simultaneous real-time measurement of EEG/EMG and l-glutamate in mice: A biosensor study of neuronal activity during sleep. Journal of Electroanalytical Chemistry. 2011; 656(1-2):106-13. PMID: 21660117
26. Gu G, Lorrain DS, Wei H, Cole RL, Zhang X, Daggett LP, et al. Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: Implication in emotional responses and central disinhibition. Brain Res. 2008; 1197:47-62. doi: 10.1016/j.brainres.2007.12.057 PMID: 18242587
27. Makoff A, Volpe F, Lelchuk R, Harrington K, Emson P. Molecular characterization and localization of human metabotropic glutamate receptor type 3. Brain research Molecular brain research. 1996; 40(1): 55-63. PMID: 8840013
28. Ohishi H, Shigemoto R, Nakanishi S, Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. J Comp Neurol. 1993; 335(2):252-66. PMID: 8227517
29. Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain research Molecular brain research. 1998; 56(1-2):207-17. PMID: 9602155
30. Tamaru Y, Nomura S, Mizuno N, Shigemoto R. Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites. Neuroscience. 2001; 106(3):481-503. PMID: 11591452
31. Wright RA, Johnson BG, Zhang C, Salhoff C, Kingston AE, Calligaro DO, et al. CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [(3)H]LY459477 autoradiography. Neuropharmacology. 2013; 66:89-98. doi: 10.1016/j.neuropharm.2012.01.019 PMID: 22313530
32. Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014; 511(7510):421-7. doi: 10.1038/nature13595 PMID: 25056061
33. Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH, Hariri AR, et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci U S A. 2004; 101(34): 12604-9. PMID: 15310849
34. Harrison PJ, Lyon L, Sartorius LJ, Burnet PW, Lane TA. The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J Psychopharmacol. 2008; 22(3):308-22. doi: 10.1177/0269881108089818 PMID: 18541626
35. Kandaswamy R, McQuillin A, Sharp SI, Fiorentino A, Anjorin A, Blizard RA, et al. Genetic association, mutation screening, and functional analysis of a Kozak sequence variant in the metabotropic glutamate receptor 3 gene in bipolar disorder. JAMA Psychiatry. 2013; 70(6):591-8. doi: 10.1001/jamapsychiatry.2013.38 PMID: 23575746
36. Sartorius LJ, Weinberger DR, Hyde TM, Harrison PJ, Kleinman JE, Lipska BK. Expression of a GRM3 splice variant is increased in the dorsolateral prefrontal cortex of individuals carrying a schizophrenia risk SNP. Neuropsychopharmacology. 2008; 33(11):2626-34. doi: 10.1038/sj.npp.1301669 PMID: 18256595
37. de Quervain DJ, Papassotiropoulos A. Identification of a genetic cluster influencing memory performance and hippocampal activity in humans. Proc Natl Acad Sci U S A. 2006; 103(11):4270-4. PMID: 16537520
38. Vinson PN, Conn PJ. Metabotropic glutamate receptors as therapeutic targets for schizophrenia. Neuropharmacology. 2012; 62(3):1461-72. doi: 10.1016/j.neuropharm.2011.05.005 PMID: 21620876
39. Ghosh PK, Baskaran N, van den Pol AN. Developmentally regulated gene expression of all eight metabotropic glutamate receptors in hypothalamic suprachiasmatic and arcuate nuclei - a PCR analysis. Brain research Developmental brain research. 1997; 102(1):1-12. PMID: 9298229
40. Haak LL. Metabotropic glutamate receptor modulation of glutamate responses in the suprachiasmatic nucleus. Journal of neurophysiology. 1999; 81(3):1308-17. PMID: 10085357
41. Gannon RL, Millan MJ. Positive and negative modulation of circadian activity rhythms by mGluR5 and mGluR2/3 metabotropic glutamate receptors. Neuropharmacology. 2011; 60(2-3):209-15.
42. Haak LL, Albers HE, Mintz EM. Modulation of photic response by the metabotropic glutamate receptor agonist t-ACPD. Brain Res Bull. 2006; 71(1-3):97-100.
43. Ahnaou A, Dautzenberg FM, Geys H, Imogai H, Gibelin A, Moechars D, et al. Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture. Eur J Pharmacol. 2009; 603(1-3):62-72. doi: 10.1016/j.ejphar.2008.12.020 PMID: 19111716
44. Ahnaou A, Ver Donck L, Drinkenburg WH. Blockade of the metabotropic glutamate (mGluR2) modulates arousal through vigilance states transitions: evidence from sleep-wake EEG in rodents. Behav Brain Res. 2014; 270:56-67. doi: 10.1016/j.bbr.2014.05.003 PMID: 24821401
45. Cid JM, Tresadern G, Vega JA, de Lucas AI, Matesanz E, Iturrino L, et al. Discovery of 3-cyclopropyl-methyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4, 3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor. J Med Chem. 2012; 55(20): 8770-89. doi: 10.1021/jm3010724 PMID: 23072213
46. Dong E, Wellman LL, Yang L, Sanford LD. Effects of microinjections of Group II metabotropic glutamate agents into the amygdala on sleep. Brain Res. 2012; 1452:85-95. doi: 10.1016/j.brainres.2012.03.003 PMID: 22453124
47. Feinberg I, Campbell IG, Schoepp DD, Anderson K. The selective group mGlu2/3 receptor agonist LY379268 suppresses REM sleep and fast EEG in the rat. Pharmacol Biochem Behav. 2002; 73(2): 467-74. PMID: 12117602
48. Feinberg I, Schoepp DD, Hsieh KC, Darchia N, Campbell IG. The metabotropic glutamate (mGLU)2/3 receptor antagonist LY341495 [2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl) propanoic acid] stimulates waking and fast electroencephalogram power and blocks the effects of the mGLU2/3 receptor agonist ly379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate] in rats. J Pharmacol Exp Ther. 2005; 312(2):826-33. PMID: 15383637
49. Fell MJ, Witkin JM, Falcone JF, Katner JS, Perry KW, Hart J, et al. N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methy l-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. J Pharmacol Exp Ther. 2011; 336(1):165-77. doi: 10.1124/jpet.110.172957 PMID: 20947638
50. Lavreysen H, Langlois X, Ahnaou A, Drinkenburg W, te Riele P, Biesmans I, et al. Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782. J Pharmacol Exp Ther. 2013; 346(3):514-27. doi: 10.1124/jpet.113.204990 PMID: 23766542
51. Salt TE, Turner JP. Modulation of sensory inhibition in the ventrobasal thalamus via activation of group II metabotropic glutamate receptors by 2R,4R-aminopyrrolidine-2,4-dicarboxylate. Experimental brain research. 1998; 121(2):181-5. PMID: 9696387
52. Turner JP, Salt TE. Group II and III metabotropic glutamate receptors and the control of the nucleus reticularis thalami input to rat thalamocortical neurones in vitro. Neuroscience. 2003; 122(2):459-69. PMID: 14614910
53. Corti C, Crepaldi L, Mion S, Roth AL, Xuereb JH, Ferraguti F. Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia. Biol Psychiatry. 2007; 62(7):747-55. PMID: 17531207
54. De Filippis B, Lyon L, Taylor A, Lane T, Burnet PW, Harrison PJ, et al. The role of group II metabotropic glutamate receptors in cognition and anxiety: Comparative studies in GRM2-/-, GRM3-/- and GRM2/3-/- knockout mice. Neuropharmacology. 2015; 89:19-32. doi: 10.1016/j.neuropharm.2014.08.010 PMID: 25158312
55. Lyon L, Burnet PW, Kew JN, Corti C, Rawlins JN, Lane T, et al. Fractionation of spatial memory in GRM2/3 (mGlu2/mGlu3) double knockout mice reveals a role for group II metabotropic glutamate receptors at the interface between arousal and cognition. Neuropsychopharmacology. 2011; 36(13):-2616-28. doi: 10.1038/npp.2011.145 PMID: 21832989
56. Lyon L, Kew JN, Corti C, Harrison PJ, Burnet PW. Altered hippocampal expression of glutamate receptors and transporters in GRM2 and GRM3 knockout mice. Synapse. 2008; 62(11):842-50. doi: 10.1002/syn.20553 PMID: 18720515
57. Yokoi M, Kobayashi K, Manabe T, Takahashi T, Sakaguchi I, Katsuura G, et al. Impairment of hippocampal mossy fiber LTD in mice lacking mGluR2. Science. 1996; 273(5275):645-7. PMID: 8662555
58. Corti C, Battaglia G, Molinaro G, Riozzi B, Pittaluga A, Corsi M, et al. The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/ neuroprotection. J Neurosci. 2007; 27(31):8297-308. PMID: 17670976
59. Pilorz V, Steinlechner S, Oster H. Age and oestrus cycle-related changes in glucocorticoid excretion and wheel-running activity in female mice carrying mutations in the circadian clock genes Per1 and Per2. Physiology & behavior. 2009; 96(1):57-63.
60. Fisher SP, Godinho SI, Pothecary CA, Hankins MW, Foster RG, Peirson SN. Rapid assessment of sleep-wake behavior in mice. J Biol Rhythms. 2012; 27(1):48-58. doi: 10.1177/0748730411431550 PMID: 22306973
61. Mrosovsky N. Masking: history, definitions, and measurement. Chronobiology international. 1999; 16(4):415-29. PMID: 10442236
62. Van Someren EJ, Swaab DF, Colenda CC, Cohen W, McCall WV, Rosenquist PB. Bright light therapy: improved sensitivity to its effects on rest-activity rhythms in Alzheimer patients by application of nonparametric methods. Chronobiology international. 1999; 16(4):505-18. PMID: 10442243
63. Albrecht U, Foster RG. Placing ocular mutants into a functional context: a chronobiological approach. Methods (San Diego, Calif). 2002; 28(4):465-77. PMID: 12507465
64. Jud C, Schmutz I, Hampp G, Oster H, Albrecht U. A guideline for analyzing circadian wheel-running behavior in rodents under different lighting conditions. Biological procedures online. 2005; 7:101-16. PMID: 16136228
65. Oliver PL, Sobczyk MV, Maywood ES, Edwards B, Lee S, Livieratos A, et al. Disrupted circadian rhythms in a mouse model of schizophrenia. Current biology: CB. 2012; 22(4):314-9. doi: 10.1016/j.cub.2011.12.051 PMID: 22264613
66. Aschoff J. Circadian rhythms in man. Science. 1965; 148(3676):1427-32. PMID: 14294139
67. Albrecht U, Zheng B, Larkin D, Sun ZS, Lee CC. MPer1 and mper2 are essential for normal resetting of the circadian clock. J Biol Rhythms. 2001; 16(2):100-4. PMID: 11302552
68. Woltering TJ, Wichmann J, Goetschi E, Knoflach F, Ballard TM, Huwyler J, et al. Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists. Bioorg Med Chem Lett. 2010; 20(23):6969-74. doi: 10.1016/j.bmcl.2010.09.125 PMID: 20971004
69. Jha SK, Ross RJ, Morrison AR. Sleep-related neurons in the central nucleus of the amygdala of rats and their modulation by the dorsal raphe nucleus. Physiology & behavior. 2005; 86(4):415-26.
70. Morrison AR, Sanford LD, Ross RJ. The amygdala: a critical modulator of sensory influence on sleep. Biological signals and receptors. 2000; 9(6):283-96. PMID: 11025335
71. Sanford LD, Nassar P, Ross RJ, Schulkin J, Morrison AR. Prolactin microinjections into the amygdalar central nucleus lead to decreased NREM sleep. Sleep research online: SRO. 1998; 1(3):109-13. PMID: 11382866
72. Sanford LD, Parris B, Tang X. GABAergic regulation of the central nucleus of the amygdala: implications for sleep control. Brain Res. 2002; 956(2):276-84. PMID: 12445696
73. Sanford LD, Yang L, Tang X, Dong E, Ross RJ, Morrison AR. Cholinergic regulation of the central nucleus of the amygdala in rats: effects of local microinjections of cholinomimetics and cholinergic antagonists on arousal and sleep. Neuroscience. 2006; 141(4):2167-76. PMID: 16843604
74. Tang X, Yang L, Liu X, Sanford LD. Influence of tetrodotoxin inactivation of the central nucleus of the amygdala on sleep and arousal. Sleep. 2005; 28(8):923-30. PMID: 16218075
75. Schwartz JR, Roth T. Neurophysiology of sleep and wakefulness: basic science and clinical implications. Current neuropharmacology. 2008; 6(4):367-78. doi: 10.2174/157015908787386050 PMID: 19587857
76. Nathan PJ, Burrows GD, Norman TR. Melatonin sensitivity to dim white light in affective disorders. Neuropsychopharmacology. 1999; 21(3):408-13. PMID: 10457538
77. Hattar S, Kumar M, Park A, Tong P, Tung J, Yau KW, et al. Central projections of melanopsinexpressing retinal ganglion cells in the mouse. J Comp Neurol. 2006; 497(3):326-49. PMID: 16736474
78. Provencio I, Cooper HM, Foster RG. Retinal projections in mice with inherited retinal degeneration: implications for circadian photoentrainment. J Comp Neurol. 1998; 395(4):417-39. PMID: 9619497
79. Abe H, Rusak B, Robertson HA. Photic induction of Fos protein in the suprachiasmatic nucleus is inhibited by the NMDA receptor antagonist MK-801. Neuroscience Letters. 1991; 127(1):9-12. PMID: 1831888
80. Colwell CS, Foster RG, Menaker M. NMDA receptor antagonists block the effects of light on circadian behavior in the mouse. Brain Res. 1991; 554(1-2):105-10. PMID: 1933319
81. Kornhauser JM, Nelson DE, Mayo KE, Takahashi JS. Photic and circadian regulation of c-fos gene expression in the hamster suprachiasmatic nucleus. Neuron. 1990; 5(2):127-34. PMID: 2116813
82. Liou SY, Shibata S, Iwasaki K, Ueki S. Optic nerve stimulation-induced increase of release of 3H-glutamate and 3H-aspartate but not 3H-GABA from the suprachiasmatic nucleus in slices of rat hypothalamus. Brain Res Bull. 1986; 16(4):527-31. PMID: 2872946
83. Mikkelsen JD, Larsen PJ, Mick G, Vrang N, Ebling FJ, Maywood ES, et al. Gating of retinal inputs through the suprachiasmatic nucleus: role of excitatory neurotransmission. Neurochemistry international. 1995; 27(3):263-72. PMID: 8520465
84. Tominaga K, Geusz ME, Michel S, Inouye ST. Calcium imaging in organotypic cultures of the rat suprachiasmatic nucleus. Neuroreport. 1994; 5(15):1901-5. PMID: 7841372
85. Brandstätter JH, Koulen P, Wässle H. Diversity of glutamate receptors in the mammalian retina. Vision Research. 1998; 38(10):1385-97. PMID: 9667006
86. Hartveit E, Brandstatter JH, Enz R, Wassle H. Expression of the mRNA of seven metabotropic glutamate receptors (mGluR1 to 7) in the rat retina. An in situ hybridization study on tissue sections and isolated cells. Eur J Neurosci. 1995; 7(7):1472-83. PMID: 7551173
87. Koulen P, Malitschek B, Kuhn R, Wassle H, Brandstatter JH. Group II and group III metabotropic glutamate receptors in the rat retina: distributions and developmental expression patterns. Eur J Neurosci. 1996; 8(10):2177-87. PMID: 8921309
88. Greenwood BN, Foley TE, Le TV, Strong PV, Loughridge AB, Day HE, et al. Long-term voluntary wheel running is rewarding and produces plasticity in the mesolimbic reward pathway. Behav Brain Res. 2011; 217(2):354-62. doi: 10.1016/j.bbr.2010.11.005 PMID: 21070820
89. Lane TA, Boerner T, Bannerman DM, Kew JN, Tunbridge EM, Sharp T, et al. Decreased striatal dopamine in group II metabotropic glutamate receptor (mGlu2/mGlu3) double knockout mice. BMC neuroscience. 2013; 14:102. doi: 10.1186/1471-2202-14-102 PMID: 24053122
90. Ikemoto S. Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain research reviews. 2007; 56(1):27-78. PMID: 17574681
91. Lammel S, Lim BK, Ran C, Huang KW, Betley MJ, Tye KM, et al. Input-specific control of reward and aversion in the ventral tegmental area. Nature. 2012; 491(7423):212-7. doi: 10.1038/nature11527 PMID: 23064228
92. Meijer JH, Robbers Y. Wheel running in the wild. Proceedings Biological sciences / The Royal Society. 2014; 281(1786).
93. Novak CM, Burghardt PR, Levine JA. The use of a running wheel to measure activity in rodents: relationship to energy balance, general activity, and reward. Neurosci Biobehav Rev. 2012; 36(3):1001-14. doi: 10.1016/j.neubiorev.2011.12.012 PMID: 22230703
94. Sherwin CM. Voluntary wheel running: a review and novel interpretation. Animal behaviour. 1998; 56(1):11-27. PMID: 9710457
95. Fallin M D, Lasseter Virginia K, Avramopoulos D, Nicodemus Kristin K, Wolyniec Paula S, McGrath John A, et al. Bipolar I Disorder and Schizophrenia: A 440-Single-Nucleotide Polymorphism Screen of 64 Candidate Genes among Ashkenazi Jewish Case-Parent Trios. American journal of human genetics. 2005; 77(6):918-36. PMID: 16380905
96. Green E, Grozeva D, Norton N, Jones I, Jones L, O'Donovan MC, et al. Variation at GRM3 influences susceptibility to psychotic bipolar disorder. American journal of human genetics. 2006; 141:697.
97. Harvey AG, Talbot LS, Gershon A. Sleep Disturbance in Bipolar Disorder Across the Lifespan. Clinical psychology: a publication of the Division of Clinical Psychology of the American Psychological Association. 2009; 16(2):256-77.